医学
经皮
软组织
烧蚀
放射科
肉瘤
软组织肉瘤
普通外科
内科学
病理
作者
Ahmed J. Awad,Koustav Pal,Steven Yevich,J. Kuban,Alda L. Tam,Bruno C. Odisio,Sanjay Gupta,Peiman Habibollahi,Andrew J. Bishop,Anthony P. Conley,Neeta Somaiah,Dejka M. Araujo,Maria A. Zarzour,Ravin Ratan,Christina L. Roland,Emily Z. Keung,Steven Y. Huang,Rahul A. Sheth
出处
期刊:Cancer
[Wiley]
日期:2024-04-20
摘要
Abstract Purpose To evaluate outcomes following percutaneous image‐guided ablation of soft tissue sarcoma metastases to the liver. Materials and Methods A single‐institution retrospective analysis of patients with a diagnosis of metastatic soft tissue sarcoma who underwent percutaneous image‐guided ablation of hepatic metastases between January 2011 and December 2021 was performed. Patients with less than 60 days of follow‐up after ablation were excluded. The primary outcome was local tumor progression‐free survival (LPFS). Secondary outcomes included overall survival, liver‐specific progression‐free survival. and chemotherapy‐free survival. Results Fifty‐five patients who underwent percutaneous ablation for 84 metastatic liver lesions were included. The most common histopathological subtypes were leiomyosarcoma (23/55), followed by gastrointestinal stromal tumor (22/55). The median treated liver lesions was 2 (range, 1–8), whereas the median size of metastases were 1.8 cm (0.3–8.7 cm). Complete response at 2 months was achieved in 90.5% of the treated lesions. LPFS was 83% at 1 year and 80% at 2 years. Liver‐specific progression‐free survival was 66% at 1 year and 40% at 2 years. The overall survival at 1 and 2 years was 98% and 94%. The chemotherapy‐free holiday from the start of ablation was 71.2% at 12 months. The complication rate was 3.6% (2/55); one of the complications was Common Terminology Criteria for Adverse Events grade 3 or higher. LPFS subgroup analysis for leiomyosarcoma versus gastrointestinal stromal tumor suggests histology‐agnostic outcomes (2 years, 89% vs 82%, p = .35). Conclusion Percutaneous image‐guided liver ablation of soft tissue sarcoma metastases is safe and efficacious.
科研通智能强力驱动
Strongly Powered by AbleSci AI